Nectin Therapeutics Licenses Antibodies to Immunome

Nectin Therapeutics, a biotechnology firm based in Jerusalem, has announced a significant global licensing agreement with Immunome Inc., another biotechnology company specializing in pioneering cancer therapies. This exclusive worldwide deal centers on a collection of antibodies targeting an undisclosed cancer-related target. The agreement grants Immunome complete rights to these antibodies, enabling them to oversee the research, development, production, and marketing of products derived from these antibodies.

Fabian Tenenbaum, CEO of Nectin Therapeutics, expressed that this partnership allows Nectin to generate value while continuing to focus on their anti-PVR program (NTX1088), which is currently undergoing clinical trials for various high-need tumor types. Furthermore, Nectin aims to advance its innovative antibody drug conjugates (ADCs) into clinical stages. Tenenbaum highlighted Immunome's proven expertise in developing and commercializing innovative ADC therapies as a key reason for choosing them as a partner.

Clay Siegall, President and CEO of Immunome, emphasized the potential of next-generation transformative ADCs to address novel targets by combining high-quality antibodies with cutting-edge linker-payload technology. He acknowledged the efforts made by Nectin in developing these antibodies and expressed enthusiasm for advancing them further.

The terms of the agreement stipulate that Nectin will receive an upfront payment from Immunome, alongside eligibility for milestone payments and royalties. This exclusive, worldwide license encompasses monoclonal antibodies targeting a singular, undisclosed molecule. Immunome will take on the responsibility for all stages of development, manufacturing, and commercialization of products that incorporate these antibodies.

Nectin Therapeutics, founded with a mission to revolutionize cancer treatment, leverages its deep understanding of Nectin pathways to create advanced immune oncology therapies and antibody drug conjugates. The company aims to set new benchmarks in efficacy and patient response for challenging-to-treat cancers. Nectin's technology tackles major resistance mechanisms in current immune oncology therapies by developing a diverse pipeline of innovative monoclonal antibodies and ADCs. The company is supported by a team of experts with extensive experience in oncology drug development and a track record of building successful biotechnology companies. Nectin Therapeutics operates as a venture-backed, privately held firm, with funding from investors such as aMoon Fund, Peregrine Ventures, IBF, Integra Holdings, the Myeloma Investment Fund (MIF), GIBF, and the Cancer Focus Fund.